Back to search

Article

Comparison of intravesical instillation of Bacille Calmette-Guérin and epirubicin: a randomized controlled trial

2020-11-03

Abstract excerpt

<title>Abstract</title> <p>Background The optimal regimen of instillation for patients with non-muscle invasive bladder cancer (NMIBC) and the recurrence-related factors are still needed to be clear. Methods The patients underwent transurethral resection of bladder tumor who diagnosed as intermediate or high risk NMIBC were randomized to receive bacillus Calmette–Guérin (BCG) 19, 15 times or epirubicin (EPI) 18...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0a387f29-3bd6-58aa-b019-417ce8c9833e
DOI
10.21203/rs.3.rs-79981/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparison of intravesical instillation of Bacille Calmette-Guérin and epirubicin: a randomized controlled trialDOI 10.21203/rs.3.rs-79981/v1
Immunotherapy in Bladder Cancer: A Systematic Review of Clinical Trials and Therapeutic AdvancesSemantic proximity
The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study.Semantic proximity
Comparing Clinical Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with T1 High Grade Bladder CancerSemantic proximity
The Potential Antitumor Effects of Combining Intravesical Therapy with Recombinant Bacillus Calmette-Guérin and an Immune Checkpoint Inhibitor in Bladder CancerSemantic proximity
Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer.Semantic proximity
Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studiesSemantic proximity
Effect of regional versus general anesthesia on recurrence of non-muscle invasive bladder cancer: a systematic review and meta-analysisSemantic proximity
Potential influence of anaesthesia techniques on the recurrence and progression after resection of nonmuscle invasive bladder cancer: a propensity score-matched analysisSemantic proximity
Management of Non-Muscle-invasive Bladder Cancer: Quality of Clinical Practice Guidelines and Variations in RecommendationsSemantic proximity
Identification of Chemotherapeutic Dihydromyricetin With Enhanced Anti-tumor Activity and Biosafety for Muscle Invasive Bladder CancerSemantic proximity
Guidance of adjuvant instillation in intermediate risk non- muscle invasive bladder cancer by drug screens in patient derived organoids. A Single center, Open-label, Phase II trial. GAIN-INST-TrialSemantic proximity
Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.Semantic proximity
Select a neighboring publication to make it the new centre.